Graft Loss Following Onset of Schizophrenia Long After Liver Transplantation.

graft loss liver transplantation schizophrenia

Journal

International medical case reports journal
ISSN: 1179-142X
Titre abrégé: Int Med Case Rep J
Pays: New Zealand
ID NLM: 101566269

Informations de publication

Date de publication:
2020
Historique:
received: 07 08 2019
accepted: 09 01 2020
entrez: 8 4 2020
pubmed: 8 4 2020
medline: 8 4 2020
Statut: epublish

Résumé

Information regarding new-onset posttransplant psychotic disorders and their effect on nonadherence and posttransplant outcome is quite limited. We report a case of new-onset posttransplant schizophrenia that led to death. The patient, a woman with Wilson disease but no history of psychiatric problems or a substance use disorder had undergone liver transplantation at age 21. She married subsequently and bore children, being well able to handle her housework, child care, and full-time employment. She continued her medications as prescribed, and good graft function was maintained. At age 41, she experienced an episode of schizophrenia, then graft loss associated with nonadherence to immunosuppressive agents. Death ensued, occurring 6 months after the onset of schizophrenia. This case highlights the possibility that schizophrenia manifesting long after liver transplantation can result in graft loss and death due to medication nonadherence. Thus, awareness of the possibility of this rare clinical scenario is critical.

Identifiants

pubmed: 32256125
doi: 10.2147/IMCRJ.S226422
pii: 226422
pmc: PMC7090152
doi:

Types de publication

Case Reports

Langues

eng

Pagination

101-104

Informations de copyright

© 2020 Anraku et al.

Déclaration de conflit d'intérêts

Professor Katsuji Nishimura reports grant and/or personal fees from Meiji Seika Pharma, Mochida, Takeda, Yoshitomiyakuhin, Pfizer, Eli Lilly, MSD, Shionogi, Janssen, Eisai, Astellas, Otsuka, Daiichi Sankyo, Nipro, Kissei, Tsumura, Novartis, Mitsubishi Tanabe, Chugai, Dainippon Sumitomo, GlaxoSmithKline, and Mebix, outside the submitted work. The authors report no other conflicts of interest in this work.

Références

Curr Opin Organ Transplant. 2014 Apr;19(2):196-200
pubmed: 24553499
Transpl Int. 2018 May;31(5):554-565
pubmed: 29405487
Transpl Int. 2018 Apr;31(4):377-385
pubmed: 28945291
Int J Neuropsychopharmacol. 2006 Aug;9(4):493-4
pubmed: 16313703
J Transl Neurosci (Beijing). 2016 Sep;1(1):37-42
pubmed: 29152382
Clin Pract Epidemiol Ment Health. 2011;7:182-4
pubmed: 22291850
Crit Care Nurs Q. 1991 Nov;14(3):51-5
pubmed: 1933544
J Am Soc Nephrol. 2003 Jun;14(6):1628-35
pubmed: 12761265
Psychosomatics. 1994 Mar-Apr;35(2):159-61
pubmed: 8171175
Gen Hosp Psychiatry. 2014 Jan-Feb;36(1):53-62
pubmed: 24120023
Psychosomatics. 1994 Nov-Dec;35(6):574-8
pubmed: 7809360
J R Soc Med. 1997 Oct;90(10):563
pubmed: 9488016
Prog Transplant. 2015 Dec;25(4):289-96
pubmed: 26645920

Auteurs

Yuta Anraku (Y)

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Rie Akaho (R)

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Satoko Matsui (S)

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Akihito Sannomiya (A)

Department of Surgery, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.

Shohei Fuchinoue (S)

Department of Surgery, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.

Katsuji Nishimura (K)

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

Classifications MeSH